Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?

被引：43

作者：

Mangen, Marie-Josee J. ^{[1
,2
]}

van Duynhoven, Yvonne T. H. P. ^{[2
]}

Vennema, Harry ^{[2
]}

van Pelt, Wilfrid ^{[2
]}

Havelaar, Arie H. ^{[2
,3
]}

de Melker, Hester E. ^{[2
]}

机构：

[1] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands

[2] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands

[3] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands

来源：

VACCINE | 2010年 / 28卷 / 14期

关键词：

Rotavirus vaccination; National immunization program; Cost-effectiveness; RISK-FACTORS; DISEASE BURDEN; GASTROENTERITIS; ENGLAND; HOSPITALIZATIONS; NETHERLANDS; INFECTIONS; EFFICACY; INFANTS; CAMPYLOBACTER;

D O I：

10.1016/j.vaccine.2010.01.014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix (R) is more cost-effective than RotaTeq (R), resulting in a cost-utility ratio (CUR) of (sic) 53,000 per DALY (third payer perspective) and (sic) 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：2624 / 2635

页数：12

共 64 条

[1] Occurrence and impact of community-acquired and nosocomial rotavirus infections - a hospital-based study over 10 y [J].

Berner, R ;

Schumacher, RF ;

Hameister, S ;

Forster, J .

ACTA PAEDIATRICA, 1999, 88 :48-52

[2] Reviewing the Cost Effectiveness of Rotavirus Vaccination The Importance of Uncertainty in the Choice of Data Sources [J].

Bilcke, Joke ;

Beutels, Philippe .

PHARMACOECONOMICS, 2009, 27 (04) :281-297

[3] Cost-Effectiveness of Rotavirus Vaccination: Exploring Caregiver(s) and "No Medical Care" Disease Impact in Belgium [J].

Bilcke, Joke ;

Van Damme, Pierre ;

Beutels, Philippe .

MEDICAL DECISION MAKING, 2009, 29 (01) :33-50

[4]

Brouwer W, 2005, HOOGTE DISCONTEERVOE

[5] Disease burden and risk factors for hospitalizations associated with rotavirus infection among children in New York State 1989 through 2000 [J].

Chang, HGH ;

Glass, RI ;

Smith, PF ;

Cicirello, HG ;

Holman, RC ;

Morse, DL .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (09) :808-814

[6] The new pentavalent rotavirus vaccine composed of bovine (Strain WC3)-human rotavirus reassortants [J].

Clark, H. Fred ;

Offit, Paul A. ;

Plotkin, Stanley A. ;

Heaton, Penny M. .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (07) :577-583

[7]

*CTG, 2003, TAR MED SPEC 1 JAN 2

[8]

*CTG, 2005, CARE201053C CTG S

[9] Hospital admissions for rotavirus infection in the Netherlands [J].

de Wit, MAS ;

Koopmans, MPG ;

van der Blij, JF ;

van Duynhoven, YTHP .

CLINICAL INFECTIOUS DISEASES, 2000, 31 (03) :698-704

[10] Risk factors for norovirus, Sapporo-like virus, and group A rotavirus gastroenteritis [J].

de Wit, MAS ;

Koopmans, MPG ;

van Duynhoven, YTHP .

EMERGING INFECTIOUS DISEASES, 2003, 9 (12) :1563-1570

← 1 2 3 4 5 6 7 →